Susan Kalota, MD
Urology · Tucson, AZNPI 1063407260
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,958 of the $29,685 with a category attached, or 77.3%. Caldera Medical, Inc accounts for 62.1% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2020 at $18,886 and has fallen 95.5% since, to $849 in 2025. Among urology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $131.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$18K
- AMAG Pharmaceuticals, Inc.$5K
- Coloplast$1K
- Axonics, Inc.$908
- Sumitomo Pharma America, Inc.$697
- AstraZeneca$527
- plus $3K from 31 others
Across 284 payments — averaging $4223.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$230K
- Pfizer$185K
- Bluewind Medical$129K
- Ferring Pharmaceuticals AS$107K
- Veru Inc.$89K
- Ferring International Pharmascience Center US$73K
- plus $387K from 8 others
What the payments were for
- Consulting fees$22,95877%
- Travel & lodging$1,3234%
- Food & beverage$5,19017%
- Education$2131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 3 | $18,436 |
| AMAG Pharmaceuticals, Inc. | 15 | $4,658 |
| Coloplast | 33 | $1,039 |
| Axonics, Inc. | 8 | $908 |
| Sumitomo Pharma America, Inc. | 29 | $697 |
| AstraZeneca | 9 | $527 |
| Astellas Pharma US Inc | 16 | $331 |
| Astellas Pharma Global Development | 4 | $330 |
| 180 Medical, Inc. | 16 | $306 |
| Cook Medical LLC | 7 | $277 |
| Amgen(2 entities) | 6 | $274 |
| Myovant Sciences Inc. | 16 | $261 |
| AbbVie(2 entities) | 7 | $237 |
| Boston Scientific | 7 | $236 |
| Bayer | 10 | $155 |
| Stryker | 1 | $110 |
| Teva Pharmaceuticals USA, Inc. | 1 | $85 |
| Novo Nordisk | 1 | $83 |
| Ferring Pharmaceuticals Inc. | 5 | $77 |
| Medtronic | 3 | $69 |
| Rochester Medical Corporation | 4 | $62 |
| Dendreon Pharmaceuticals LLC | 4 | $59 |
| Urogen Pharma, Inc. | 3 | $50 |
| Integra Lifesciences Corporation | 1 | $50 |
| Johnson & Johnson | 2 | $49 |
| Progenics Pharmaceuticals, Inc. | 2 | $46 |
| Merck | 1 | $44 |
| Tolmar Pharmaceuticals, Inc. | 2 | $37 |
| Smith+Nephew | 2 | $33 |
| Tolmar, Inc. | 1 | $28 |
| Novartis | 1 | $23 |
| Pfizer | 1 | $21 |
| Blue Earth Diagnostics | 1 | $19 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $18 |
| Sanofi | 1 | $17 |
| Calyxo, Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$18,417
- MAKENA$4,098
- Bulkamid$738
- Axonics r-SNM System$738
- ALTIS$503
- Cook$190
- RESTORELLE$142
- TEZSPIRE$125
- BOTOX$125
- Tavneos$122
- LithoVue Elite$110
- FlowTriever$110
How this compares
$29,685 in reported general payments places this provider in the 90th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 281 | $228,429 |
| GemtesaVibegron | 196 | $173,241 |
| Estradiol | 322 | $21,375 |
| Fosfomycin Tromethamine | 90 | $18,091 |
| Trospium Chloride | 207 | $12,130 |
| Potassium Citrate ErPotassium Citrate | 70 | $8,140 |
| Methenamine Hippurate | 65 | $7,289 |
| PremarinEstrogens, Conjugated | 15 | $7,288 |
| Solifenacin Succinate | 176 | $6,413 |
| Tolterodine Tartrate ErTolterodine Tartrate | 34 | $6,013 |
| Tolterodine Tartrate | 88 | $4,048 |
| Cephalexin | 370 | $3,854 |
| Tamsulosin Hcl | 152 | $2,581 |
| Oxybutynin Chloride ErOxybutynin Chloride | 191 | $2,405 |
| NitrofurantoinNitrofurantoin Macrocrystal | 59 | $1,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $331 | $228,429281 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $697 | $173,241196 claims |
| PfizerPremarin | $21 | $7,28815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 269 urology providers in Arizona.
Other urology in Tucson
- Mitzi BarmatzTucson$135K
- Curtis DunsheeTucson$46K
- Kalpesh PatelTucson$26K
- Tristan BerryTucson$14K
- Aleksandar BlubaumTucson$11K
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
- Rahul MehanMesa$277K
- Chinedu MmejeGilbert$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.